The debate over how long women should use bone density drugs, known as bisphosphonates, for osteoporosis continues especially after the Food & Drug Administration published an analysis of the safety of long term use of bisposphonates, such as Fosamax. The analysis published in the New England Journal of Medicine, reveals the FDA is concerned that the use of bisphosphonates actually contributes to rare but serious adverse events associated with bisphosphonates, such as atypical femur fractures,

On June 23, 2011, the United States Supreme Court ruled that lawsuits against generic drug manufacturers are preempted by federal drug regulations which require a generic drug label to match the brand warning label word for word regardless of mounting evidence that a generic drug carries a risk far greater than what is disclosed in the label. The case is Pliva v. Mesing. Writing for the Court, Justice Thomas noted that if Mesing and Demahy

Osteoprosis Drugs & Femur Fracture National Public Radio (NPR) reported on unique fractures associated with use of osteoporosis drugs.  NPR reported about a rare bone fracture and discussed what happened to Dr. Jennifer Schneider as she was travelling on a New York City subway when the train jolted and she shifted her weight onto her right leg. Suddenly, her thighbone snapped and she collapsed to the floor. “I could hear it and I could feel

Bone density drugs for treatment of osteoporosis have become the standard treatment for women suffering from this disorder.  However, a growing number of case reports describe women who developed fractures involving the femur after long term bisphosphonate therapy.  Fosamax is one   bisphosphonate drug.  The Journal of American Medical Association published on February 23, 2011 a major study entitled: Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women. http://jama.ama-assn.org/content/305/8/783.short.  The study